Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-06
DOI
10.1186/s13045-020-01017-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
- (2020) Siddhartha Ganguly et al. BLOOD
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study
- (2020) Yu Wang et al. Science China-Life Sciences
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2020) Ali Bazarbachi et al. HAEMATOLOGICA
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
- (2020) Chong Chyn Chua et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
- (2020) Jorge E. Cortes et al. Journal of Hematology & Oncology
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
- (2020) Musa Yilmaz et al. Journal of Hematology & Oncology
- Sorafenib prevents AML relapse after allo-HSCT
- (2020) Diana Romero Nature Reviews Clinical Oncology
- Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
- (2020) Lei Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
- (2020) Melat T. Gebru et al. Journal of Hematology & Oncology
- Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Li Xuan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update
- (2019) Giorgia Battipaglia et al. Clinical Lymphoma Myeloma & Leukemia
- Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
- (2019) Simona Piemontese et al. Journal of Hematology & Oncology
- Maintenance therapy in AML: The past, the present and the future
- (2019) Matteo Molica et al. AMERICAN JOURNAL OF HEMATOLOGY
- Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia
- (2019) Yunju Ma et al. BONE MARROW TRANSPLANTATION
- Recent drug approvals for acute myeloid leukemia
- (2019) Catherine Lai et al. Journal of Hematology & Oncology
- BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML
- (2019) Mark J. Levis et al. BLOOD
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
- (2018) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
- (2018) Li Xuan et al. CANCER
- Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies
- (2018) Kathryn T. Maples et al. LEUKEMIA & LYMPHOMA
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- (2018) Catherine J. Lee et al. BONE MARROW TRANSPLANTATION
- Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
- (2018) Yuxin Liu et al. BLOOD REVIEWS
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
- (2018) Uwe Platzbecker et al. LANCET ONCOLOGY
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
- (2017) Thomas Schroeder et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Emerging therapies for acute myeloid leukemia
- (2017) Caner Saygin et al. Journal of Hematology & Oncology
- Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
- (2017) G Bug et al. LEUKEMIA
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- (2015) Iskra Pusic et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
- (2015) J. Wellbrock et al. CLINICAL CANCER RESEARCH
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents
- (2014) Dario Ferrero et al. ANNALS OF HEMATOLOGY
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
- (2014) Gaku Oshikawa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis
- (2013) Oliver Teuffel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
- (2013) D J DeAngelo et al. LEUKEMIA
- Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine
- (2013) T Maeda et al. Blood Cancer Journal
- Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
- (2012) C.-H. Yan et al. BLOOD
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
- (2009) Elias Jabbour et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now